RecruitingPhase 2NCT05337618

Improving Neurotrauma by Depolarization Inhibition With Combination Therapy (INDICT)

Improving Neurotrauma by Depolarization Inhibition With Combination Therapy (INDICT): a Phase 2 Randomized, Feasibility Trial


Sponsor

University of Cincinnati

Enrollment

72 participants

Start Date

Dec 16, 2022

Study Type

INTERVENTIONAL

Conditions

Summary

This study is a randomized Phase 2 trial to determine the feasibility of real-time electrocorticographic monitoring of spreading depolarizations (SD) to guide implementation of a tier-based protocol of intensive care therapies, aimed at SD suppression, for the management of patients who have undergone acute operative treatment of severe traumatic brain injury.


Eligibility

Min Age: 18 YearsMax Age: 80 Years

Inclusion Criteria1

  • (1) clinical indication for emergency craniotomy with dural opening to treat acute TBI within 72 hr post-trauma

Exclusion Criteria3

  • persistent bilateral non-reactive pupils or other evidence of non-survivable injury,
  • decompressive craniectomy to treat refractory ICP subsequent to diffuse injury, (3) co-enrollment in another therapeutic TBI trial, and
  • (4) pregnancy

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIAGNOSTIC_TESTFull-band Electrocorticography

Diagnosis of spreading depolarizations in continuous electrocorticography

COMBINATION_PRODUCTTreatment Algorithm

Protocol for escalation and de-escalation of physiologic-targeted and pharmacologic therapies to treat and prevent spreading depolarizations


Locations(1)

University of Cincinnati

Cincinnati, Ohio, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05337618


Related Trials